hVIVO (LON:HVO) Trading Down 44.5% – Should You Sell?

hVIVO plc (LON:HVO)’s stock price dropped 44.5% during trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 9 ($0.12). Approximately 79,187,813 shares changed hands during mid-day trading, an increase of 2,238% from the average daily volume of 3,386,995 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Ratings Changes

Separately, Shore Capital reaffirmed a “buy” rating on shares of hVIVO in a report on Thursday, April 10th.

hVIVO Price Performance

The firm has a market cap of £62.90 million, a PE ratio of 3.67 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The stock has a 50 day simple moving average of GBX 16.30 and a 200-day simple moving average of GBX 18.26.

hVIVO (LON:HVO) last posted its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Buying and Selling at hVIVO

In other news, insider Yamin Mo’ Khan sold 3,062,246 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($702,634.39). Insiders own 14.03% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.